Trial Of Parkinson’S And Zoledronic Acid
Posted Date: Apr 30, 2021
- Investigator: Alberto Espay
- Specialties: Movement Disorders, Neurology, Parkinson's Disease
- Type of Study: Drug
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.
Criteria:
• Men And Women Age 60 Or Older. • Current Parkinson’S Disease Or Neurodegenerative Parkinsonism Diagnosis (Including Progressive Supranuclear Palsy, Multiple System Atrophy, Cortical Basal Degeneration, Vascular Parkinsonism, Dementia With Lewy Bodies Or Another Form Of Neurodegenerative Parkinsonism) • Not Confined To Bed Or Wheel Chair • Willing And Able To Continue In Follow-Up For Up To 5 Years • Willing And Able To Provide Informed Consent. A Legally Authorized Representative May Provide Informed Consent For Those Who Are Unable To Consent For Themselves.
Keywords:
Parkinson's Disease, Neurology, Espay
For More Information:
Christina Gruenwald
513-558-0112
gruenwcm@ucmail.uc.edu